Therefore, it is suggested that the mechanism of action of both compounds could be associated with PPARγ agonism, although it is not ruled out that 3b and 4y may also act on other molecular targets, thus preventing micro- and macrovascular complications of T2D. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.